Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
finerenone + semaglutide
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
Finerenone + semaglutide is an investigational combination of two distinct therapeutic agents being evaluated for the treatment of chronic kidney disease (CKD). Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) developed by Bayer and marketed under the brand name Kerendia, which targets the mineralocorticoid receptor to reduce inflammation and fibrosis in the kidney and cardiovascular system. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and marketed under brand names such as Ozempic, Wegovy, and Rybelsus, which targets the GLP-1 receptor to improve glycemic control, promote weight loss, and provide cardiorenal protection. The combination is being studied in clinical trials, such as the Phase II FINESSE-CKD trial sponsored by the University Medical Center Groningen, to evaluate its synergistic effects on reducing albuminuria and slowing the progression of CKD.
- Other names
- finerenone and semaglutidesemaglutide + finerenonesemaglutide and finerenone
02
Targets
GLP1R (GLP-1R)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on finerenone + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on finerenone + semaglutide.